Well said. We are buying management a lifestyle and padding Peter’s bank account in the Cayman Islands ( he has a shell company over there ). Nothing in return for investors...
For starters, we are at the 52 week low, and the high ~ $12-$13/ sh over the last 3 yrs which was after the merger is around a 8-10 X multiple (typical of an early stage bio). Big players have not sold and the MRKR portfolio is still strong. The share price is where it is because it’s being shorted like most low market cap low volume biotech. This will change soon. I remember Peter mentioning that Dr. Vera will be making a presentation on the manufacturing side this fall and I believe that will create significant price appreciation; maybe even a short squeeze.
News 
Market Data 
Discover 
AI
